Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Carasent, Audiocast with teleconference, Q1'24

By Inderes4/24/2024, 6:00 AM
Carasent

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Daniel Öhman
00:02 - 22:02

Hi, and good morning. Welcome to Carasent's Q1 earnings call. My name is Daniel Öhman. I'm the CEO. With me, I have Svein Martin Bjørnstad as CFO. And we will start with me giving some highlights and then a company update, and then Svein Martin will give a financial update. Looking at the highlights for the first quarter. I hope that you all have seen that we have released new financial targets yesterday after, uh, after working hours. And the background of that is that we've seen a good increase in new customer contracts. We have had more efficiency gains than we had planned for. We have sold Medrave and we have continued very low churn. So that gives us very good visibility on this year and the next year. And I will come back to that and give more details later in this presentation. Other highlights is that we have a new agreement with VGR in Sweden regarding Medrave and Medrave. Is our system to follow up the quality of care in primary care and also to automate reporting to national quality registries. And this agreement is now changing. VGR's choice system for the region. And then they have procured the Medrave functionality for the new e-referral system, and the ARR from this new contract is 11 million. The ARR from the old contract was around 5 million. So there's a 6 million increase. We also have 2 million of consultancy fees connected to this that will occur this year. And in most respects, this is basically a price increase we're doing. It might sound like a lot, but the background is also that Medrave has had a lot of new functionality since VGR procured the last time. So we are actually increasing the price to catch up on that. And in general, I think we have quite good pricing power that we need to use, especially in that product. So it's mostly a price increase when they update to a new system in the sector. And we have also released our surgery e-referral solution in Stockholm for Confrere. So e-referrals is that if you use the region's usual system in Stockholm, you can send referrals directly to our clinic, the clinic using Confrere. It used to be before this that if you had used Confrere in Stockholm, you had to transfer the referrals by hand from the public system to your own system. And that's quite cumbersome and really makes it more difficult to sell Confrere where you have to transfer all those by hand. The first pilot says that he can add one more patient per day thanks to this solution. I think that's a bit optimistic. It's an optimistic view, but I think it's an important point he is making. And that is that if we look at the use of our systems, they typically cost around 2% of the turnover if they use a lot of our systems and solutions. So we take roughly 2% of the turnover from our customer. But forecasts also tell a lot about how it is to work within that clinic or hospital. So our systems are extremely important when it comes to driving your processes internally, driving profitability, all these parts. So if we're really good at selling those kinds of solutions and really developing them to fit our customers, if we charge 2% or 2.5% of their revenue, it doesn't matter that much. They have mostly fixed costs. So to make sure that our systems are always up and running, never down, then we keep improving, making sure that they can do as much as they can and help as many patients as possible. Each day we sit in a really good position. When it comes to growth. ARR not implemented. ARR is now up to 40 million NOK. It was 2 million NOK at the same time last year. And this will propel our growth next year, of course. And gives us this visibility of where we're heading in a really good way. And if we look at sign or at this point in time, compared to the same time last year, we have an organic growth of 20%. And I think this is the most important number for us to look at. This is what says what will drive our growth going forward. And ARR is by far the most important type of revenue for us. We are more and more moving from consultancy fees to ARR. And in any agreement we do, we make sure to really focus on the ARR. So for example, the new agreement with VGR, we have focused on getting well paid for our ARR. We have low churn. This contract will last for a long time. The implementation and the consultants were connected to that. And that's quite big in that contract. We sell as roughly half what we usually charge. It's enough to, you know, pay for our costs. But it's not where we make our profit. It's not from the consultancy fee. It's the same in VGR. We only charge 2,000,002 to get migrated into the new HR system. But it's the ARR we're focusing on. And in the long term, that will really help us because it adds every year. Looking at profitability, we have done additional cost savings. Um, and I think this is also an important point. Um, last spring we did the big cost savings program, which changed the entire structure of the company. We put a lot of new people into new roles. And then, of course, if you do those kinds of changes and so much changes, not everything is perfect. Day one. A big part of running a business is to every day become a little bit better, and over time that creates a lot of improvement. And we continue to get every day a bit better. And what we've done since then is looking at different roles to see if they are needed or not needed. Did we get that right? And so on, so we can get more and more efficient and keep getting more efficient going forward, which I really look forward to. And every role. When someone leaves, we take a hard look at it and think, can we find another way of not having to hire a new person? Kevin moved from consultants to employees. Can we lower our COGS and so on. And this has led to, uh, quite significant, uh, year-over-year improvements when it comes to EBITDA and EBITDA, excluding Webdoc X. And I think we should always be excluded when looking at this measurement on how we're doing, because Webdoc X is using our position, our knowledge, to create value in a completely new market for us. So it has nothing to do with the present business. But the EBITDA, excluding Webdoc X, goes from -11 million to plus 1 million. So that's a big improvement. And we also actually cash flow positive in the first quarter. Looking at our financial development, um, in the quarter we only have organic growth. Um, but um, the previous numbers actually include Confrere when you compare the revenue and all the other measurements of course. Uh, and you can see here that the EBITDA is improving quite rapidly, um, from back. And you can also see how we continue to invest a larger share than we used to in maintenance. And this is, I think, uh, the most important part to win new customers is that they really see that all of our solutions really help them every day, that there are no bugs. It's always up and running. And that maintenance is really important to give us pricing power and also to drive sales. This is a more important part to drive sales than new functionality. The systems are stable. They work really well. There are no bugs. They're always up and running because all of our solutions are mission-critical. You cannot run a healthcare clinic or hospital without the HR system up and running. So when there are bugs, when there's downtime, it really hurts the production of our customers. On this slide, you can really see how we are scaling into our cost base. Revenue has increased by 7 million NOK, and a combination of growth and cost savings lead to a large improvement in EBITDA of 30 million. It's also worth mentioning that at the same time, we are investing in compliance, marketing, and other functions. So we're not just saving money. We're trying to become a much better company by also spending more money on new things that we didn't spend on before. So it's a combination. But in total, of course, we are saving money going forward. Growth in ARR drives very limited costs. So that's really what I like compared to my previous business of running clinics. Here, new revenue does not at all drive costs, especially when it comes to R&D; consultancy is a bit different, and as I hope you know, within Webdoc X and most of our products, we do not have any development for specific customers. The consultancy then is just implementation projects and helping customers with education and so on. But some of our products have some development for specific customers also. And if we continue to focus and as we do continue to focus on efficiency, we will see excellent effects on the bottom line from our growth. And looking at what we've done to drive sales, I would say the first three points are the ones where we have gotten traction; the last two, we're not really there yet. The focus on customers is going from kind of an internal focus that we used to have to an external focus where we really discuss and meet our customers, look at what makes us more attractive in their eyes. That's the most important point, and that led us to choose what to develop, how to improve our products, how to improve our delivery, and to always, of course, then become also more efficient in doing those things. We have invested a lot in marketing. We have new web pages for almost all products now. I think there's 1 or 2 lacking still, but almost all of them have new stories around them, new web pages, new marketing material. We are also running a lot of ads in different forums. And most importantly, we're trying to generate a lot of leads, with different types of efforts and build the marketing department based on really generating leads for our sales team to work with. We have started with outbound sales efforts. We're not really there yet. It's supported by the change in how our salespeople are paid. They now have a much larger share of the payment being dependent on how much they as individuals sell. It used to be mostly fixed salary. So I think that will also help. Um, but it's an ongoing effort to move in that direction and also to learn how we best approach a customer, which is, you know, semi-warm. I would say that most of our potential customers are using an HR system, which they are not very happy with. I think that most of them feel that they would be better off using Webdoc X, but you have to convince them to really take the leap and take on all the work involved in changing systems. And as all of our customers mostly have fixed costs, it's really expensive to have any downtime. Also, when changing your system. So you're a bit reluctant to do that. And it also creates a lot of turmoil within a clinic or hospital, typically to change systems. And that's why our delivery team is so important. And they do a great job. And what we're trying to market at the moment, more and more, is that it's quite easy to change the web. Doctor, you can import all your old medical records. The customers that we do move, they are really happy with the change. When we ask them a month after the change to Webdoc X, 'Are you happy?' they affirmatively respond. We get really good responses. And I think to do more marketing around that will really help us because I think that's a major obstacle to changing systems. I especially look forward to surgery e-referral. This has given effect. Um, if we look, um, now, as I mentioned previously, we have 40 million of signed but not implemented. ARR that's up from 2 million before. And if we would add that, it equals a 6% growth on top of the growth rate I have, and the major new contracts, in Norway, it's Medrave involved, in Sweden for Webdoc X. It's capital and joint venture for my region. Uh, so, uh, we're winning customers from, from, uh, many of our competitors at the moment. And I think we also have quite a strong potential pipeline of new contracts, large ones. It's connected both to the study, which I think will really help drive web growth even further. But also in Norway, we need new contracts for accuracy and ad ops. That's extremely important. We are not close to where we need to be at the moment with those products. So, uh, it's really needed, but it's also ongoing life. Strong belief in us securing further contracts. Looking at new functionality to drive growth. I already mentioned referrals. I really look forward to our work on the patient journey within Webdoc X. Today in healthcare, you still send a lot of snail mail. You have a lot of phone calls. It's really cumbersome to be a patient, and it's also cumbersome to be the caregiver because you have to send all this post, and then people don't like what they see in the post, and they call you and so on. And this takes really a lot of time and effort from the clinic and makes it difficult to plan your days. And within Webdoc X, we have a lot of functions that really can help the caregiver be much more efficient and just get rid of all the snail mail, the phone calls, and so on. But we need to make sure that it's a really good experience throughout, and we need to sell it as an experience and a process, not sell it as different functions. And me as a customer, I would have loved what we can do within Webdoc X in a way that almost no other system I've seen can do. So it's really something we can work with. We've been talking about the new functionality before and that it's not growing as fast as we wanted here. You see the number of tests in that new functionality from August 22nd to March 24th. And you have this really exponential growth. And this is how it typically looks with software. Yes, but especially in healthcare, you need to have some first users. Then they tell some other users. And then more and more users get to know about the product. It's difficult to sell a product that you don't know, to get someone to buy a product that they have no references for. Because you're quite careful within healthcare. You really don't want to take risks as a healthcare provider, and it's all in the mentality of a healthcare provider. So here you can really see the growth. We hope it continues this way. You never know, of course, but it's a good sign. And in total, we have new customer growth of 5%, a net retention rate of 110%. So when we talk more about it. And all this leads us to our new targets. And with the backlog and cost control, we have high visibility of our results going forward. And if you look here at 2023, compared to 2024, 2023, of course, includes comparisons. But the difference between 2023 and 2024 is a combination of the savings we already have done, and growth and continued cost control. So we feel it's quite a lot in our hands to make sure this happens and that this is very doable. Looking at 2024, 2025, more of the improvements come from high growth and continued cost control, of course, but growth is a larger part of the improved results. But the growth here, the increase from 24 to 25, is roughly 15 million. Note that's what we have in the backlog for next year. So we basically know that we have that extra revenue. Then, of course, we have to continue to sell well in all of our products and have the underlying growth that we already had that needs to continue. We need to improve it a little bit. But most of the difference between these two years, we already have in the backlog. So we feel quite good about this. Looking at the financial performance in the first quarter. We have shown you this structure before. To give you a good view on how the different parts of Carasent are doing. We have the major part, which we call operations, which is the part that is quite healthy. It's 86% of our revenue. So almost all of it. There we have 16% growth. EBITDA continues to improve and especially EBITDA improves from 0 to 8 million in the quarter. So quite a good improvement there. When it comes to the parts where we have a little bit more challenges, we have HP and the operations we used to have also, but it's been sold. It's 30% of our revenue. There we have a lower growth, so it's important to keep going. The signs are very positive when it comes to HP, as you saw in the previous graph. For the operations, we still have some work to do when it comes to growth, but costs are under control within these two products now, which is really good, as you can see from the EBITDA, going from -4 to -1 million. And we expect to continue to improve that during the year. In Webdoc X, we have improved somewhat. And we keep going from consultants to employees in that project. So that will also help us save money. And HQ has improved a bit. So looking ahead, we aim to continue with strong organic growth. A lot of it is already in the backlog. I look forward to introducing new functionality that will drive sales even better. Efficient use of resources is, of course, extremely important when it comes to driving profitability. And, in this quarter, we did have additional cost savings. And those are the only one-offs that we have adjusted EBITDA and EBITDAC with, which is the cost of the related layoffs of 1.7 million. And it's a bit all over the organization where we think that here we can become a bit more efficient, but it also comes from. Every time someone leaves, we look at, do we need to replace this role or not? And can we replace it with someone internal and always become more efficient? And finally, which is an extremely important part, in the slightly more long term is the launch of Webdoc X. The development area is focusing on certifying the system for Germany so that someone working for the public system in Germany can start using Webdoc X. We hope to do that within the coming six months. And we are also working with acquisitions, as you know, from before, I think it's an important part of rolling out Webdoc X in Germany is that it cannot be a complete greenfield, and then it will take too long and be a bit too expensive. So we are looking for an acquisition to support them, to have a customer base to work with. But we have to make sure that we buy the right company and that that target, that system of that company is ready to be replaced. And it doesn't have too much functionality because then it will be too difficult. So, but I think we have good dialogues and look forward to continuing that work. But nothing I can go into more details now. Having said that, I will hand over to Svein Martin Bjørnstad.

Svein Martin Bjørnstad
22:03 - 31:53

Thank you, Daniel "hman. Although we don't see all the effects of the recent operational advancements in the figures. Yes, we are starting to see that our financial metrics are also improving rapidly. Revenues in Q1 were 67 million, up 12% from last year, and we now have a signed ARR base of 260 million, which grew organically by 20%. Our net retention rate was 110% in Q1, which shows our very solid basis for growth. And if we hadn't succeeded at all on the new sales side, we would still have grown 10% last year. Our margins are also improving. We had a 12% adjusted EBITDA margin in Q1 and a -7% EBITDA minus CapEx, and that's including all the investments in Webdoc X. So quite some details on this slide. But in summary, we are seeing major improvements on several levels. As you see on the top pair, Webdoc X grew 25% year over year. And adjusting for currency, 21%, which is still a major uptick compared to the level we saw last year, which was around 15%. And that shows that Webdoc X is gaining momentum on both the new site, new sales and also upsell to existing customers. Our order year is growing at a steady pace. Uh, here. You see that? The platform products, which are HpaI and Medrave, declined. But that was due to the divestment of Confrere. And adjusting for this, we had a 10% organic growth in this category as well. And our consulting revenues are down. And this is because we prioritize recurring revenues at basically all levels of the organization, as Daniel mentioned. Our gross profit increased quite significantly from 80% last year to 84% this year. Um, and this is driven by two main factors. Firstly, we have done a procurement process in Norway for a new hosting supplier, and that cut our cost by close to 50%, on a run rate basis, around 2 to 3 million per year. And also the divestment of Confrere and the positive effect on the margins, given that it was very dilutive on gross margins. Same period last year. Personnel expenses increased 5 million. Um, however, this was driven by a decrease in capitalized development expenses of more than 10 million. So, um, this is what we have talked about, that we prioritize our core products in our core markets, and then we capitalize fewer costs. Also, we have the one-off on the personnel expenses of 1.7 million related to the layoffs in the quarter that will drive cost savings going forward. Uh, so in total, EBITDA increased from 2.3 to 6.3 million. And adjusting for the layoffs, we had the adjusted EBITDA of 8 million in Q1 and, EBITDA minus CapEx of 4.9. And we had a positive EBITDA minus CapEx, excluding the German expansion project. Recurring revenues grew organically by 15% in the quarter, which is also a step up compared to the level we have seen in the last few years. Um, and it was driven by a strong net upsell of 12%, where approximately a bit less than half is related to price increases, and the other half is that we continue to sell more services to our customers and that they continue to grow. Churn is very low at, uh, 2%. And the new customer growth in the quarter was 5%, which is quite in line with what it has been in the last few years. However, we now see that all the initiatives on the sales side are starting to pay off. Um, and we see that the ARR, including the signed, not implemented ARR, is increasing quite rapidly, mainly as a result of the new large contracts. We have one. So looking at the signed ARR last year, it was 211 million and with constant currency. We had the organic growth of 20%. Um, and you can see that it is driven by the strong growth in the revenue backlog that increases from 2 to 14 million. Uh, combined with the strong underlying basis we have with a net retention of around 110% and the bread and butter, new sales, of around five. In addition, churn is very low, 1.7% for the group. And that's even lower. Uh, if we exclude the press which has seen some churn. It's closer to 1%. And that clearly shows that our system is really critical to our customers. And in addition, as Daniel mentioned, we. Are a quite small fraction of their cost. So that combination is very powerful in terms of our churn and also our pricing power in the long term, I would say. Another highlight in Q1 is that we had a positive cash flow. Our operating cash flow was around 13 million. And the increase was partly driven by the improvements in profitability, but also in Q1, we have quite strong working capital effects as some of our products do annual invoicing for their customers. This of course varies. Will vary a lot from quarter to quarter. But in general, our working capital profile is very attractive and supportive to our cash flow. Given that we invoice our customers in advance. That could be like three months in advance. Or 12 months or one month. And then we pay our invoices in arrears. So it's a positive effect that we will have in the long term as well. Investments or CapEx is significantly down from 25 million to 13. And in total we are cash flow positive. Slightly. But it is a milestone for us. And our profitability is also improving rapidly. On the left-hand side, you see that our. Cash profitability, excluding Webdoc X in Q1, is a positive improvement of €12 million year. And then Q2 will be close to break-even, even including Webdoc X. And the main uncertainty in our business and profitability development is basically how fast we can grow our revenues. Given that the cost side is very much in our own control. And combining the large contract we have won with the underlying net retention and the bread and butter sales that we have delivered the last few years means that we now have much of the growth for 2024 and 2025 already secured. And this just gives us a very strong visibility that the margins will improve rapidly as well. This was faster than we anticipated and also at a lower cost. Given that we expected that the new ARR we would generate would require more resources than the contracts we have signed. So in general, all our businesses are highly scalable, and if we manage to continue to grow our revenues, our margins will expand rapidly also in the long term. So with that, we can open up for questions.

Unknown
31:54 - 32:25

If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. There are no more questions at this time, so I hand the conference back to the speakers for any remaining questions or closing comments.

Svein Martin Bjørnstad
32:27 - 32:44

Okay, so we have received quite a few questions here. The first one is from Erasmus Pearson. Can you talk about the tender for the region, Stockholm and Gotland, and any risk you see if they move to a closed system?

Daniel Öhman
32:45 - 35:59

So I would say that today, Stockholm is essentially a closed system, which we are opening up. Because in Stockholm, in theory, you can choose any system you want, but if you choose another, then the regional system, then you have to transfer all referrals by hand. Or if they want some referrals, they have to send you a letter in the post. And no one refers a patient with a letter in the post. That's just a lot of work that they don't want to do. So everyone has to transfer patients by hand, or as we now can do with the help of an RPA solution, a robotic solution. We can transfer patients between the systems. And I see us doing similar things with all other systems in the regions. So that our customers are free to choose systems, even if the region wants it or not. That's our aim. I think they are essentially closed today. What they say is that the private providers will be allowed to use the public system. So what they say so far, but it's not a demand. And Stockholm has generally been like that. I think that they will continue to be like that. So, I feel very positive about Stockholm. That's a couple of years in the future. So now we talk about the system that will be deployed in 2029, 2030 somewhere. And so it's quite a lot in the future. But at that point in time, I think it will be very positive for us, because the major obstacle for us is getting people to change systems. They know that they will be happier with what we offer than what they have. But it's a lot of work to change systems. And as you have seen in the press, there are problems from time to time, typically within healthcare, or people are not very happy about changing systems. So, if you own a private practice or a hospital group or something like this, you're very reluctant to make those changes unless you feel really, really confident. That's good. So that's our major obstacle. And this strategy will fix that for us because everyone will have to change systems. Also, I think everything points to us winning that process. And those are the ones we're winning customers from in Sweden at the moment. Uh, so I think you saw that I had a copy in a picture showing that we want for them. So we had resigned, I think it was eight clinics that moved from Cambio to Webdoc X now, uh, so I think that's, uh, a very positive thing for us. I think they're in a closed system. I think it would be less closed going forward. And also, uh, what the government, uh, is initiating in this area is to increase interoperability between systems. There is also a new EU regulation on the same thing. So I think, uh, in the longer term, we're moving to a more open environment and not a closed environment. But it's something we have to always look at. We have to be there, we have to push for it, and we have to discuss with different parties. Um, yeah.

Svein Martin Bjørnstad
36:00 - 36:10

Uh, next one, you had a workshop with Capio a few years ago, uh, where you talked about sharing information between your systems. Any update on the progress here?

Daniel Öhman
36:11 - 37:28

Yeah. I don't know that specific, uh, workshop. Uh, but, um, as I mentioned just now, uh, there is a push from both the government and the EU on increasing interoperability between systems. There is even a government, uh, training, as you say in English, uh, the investigation into new legislation, uh, where they're looking at interoperability between the systems. Uh, you have a lot of new things coming out, for example, uh, EHR which means that, uh, any user of a new system should be able to see all medication, uh, given by any other, uh, healthcare provider in Sweden. So that will really help and lessen the demand for interoperability between the systems themselves. Uh, we also have Confrere, that is part of Alphacode, where you can really also look at the medical records from other institutions, even if they use a different system or not. So I don't think the solution is really to have a one-on-one integration with Cambio. It is moving in a direction that society is moving with more and more interoperability between systems. Uh, yeah.

Svein Martin Bjørnstad
37:29 - 37:40

Um, great. There's talk about national taxation, uh, how large part of revenue within Webdoc X is from doctors and physicians within national taxation.

Daniel Öhman
37:41 - 39:51

So I think, uh, national attention here, I think, is talking about establishing a, uh, what you call in Sweden. Uh, so, uh, that is that, uh, doctor or therapist or psychologist, they, uh, have an agreement with where they can, uh, on their own just, uh, take on patients without the region having any, any say in it. Um, in general, it's a bit mixed, but, um, and there is always discussion on should that continue or not. Uh, I think that it was introduced in the 90s, uh, with the, the right-wing government at that time said that we need to increase competition, and then you were allowed to leave the hospital and then you didn't have to win the tender. You could just get this agreement with the government that you can charge the region for any care you provide within certain limits that it was about to be closed down. Um. Back in August around 2000. A little bit later, uh, the Social Democrats didn't like this at all. Then when we got, uh, the Reinfeldt, uh, government, they started allowing those, uh, contracts to be sold. So there were no new contracts awarded, but then they started selling them between themselves. So doctor to doctor, nurse to nurse, therapist to therapist to fix the rates and so on. And ever since then, it's been really difficult for the regions to close this down, uh, because, uh, individual doctors and, and therapists have paid a lot to get those contracts. So that's been discussed since the 90s. Uh, if that happens. No, I don't know, the reason why the region wants to close this down is that they don't really have control over these doctors and face-to-face, and they want to have control. They want to tender those agreements instead. I don't think we're very dependent on those agreements. Um, but I also don't think they will disappear. It's been an ongoing discussion for quite some time. Uh. But I would say that it's not the major problem for the regions. So it is not really a big push, but we'll see. Um, next.

Svein Martin Bjørnstad
39:51 - 40:51

Question, can you please provide the split on retention? How much is price increase? Um, I mentioned it briefly in the presentation, but, um, if we look at our net retention, it's composed of 12% net upsell and 2% churn. Um, basically, and on the net sell side, price is close to half of it. So 5 or 6%. And the remaining is that we have seen, um, quite a strong momentum for several of our add-ons, for example, boardroom, uh, recently. So um, uh, so that's one part of the upsell. And the other part is the volume growth. So that's the remaining, uh, six, 7% in addition to price. Next question from Phillip. Uh, can you elaborate on the momentum in the sales from smaller contracts?

Daniel Öhman
40:52 - 42:07

Yeah. Uh, so is it talking then? It's mostly Webdoc X, winning a lot of small contracts all the time. And, uh, we have good pace in small contracts. Uh, what really drives growth to get the extra growth, we need also large contracts. So, uh, in Q1, we had, uh, Joint Academy, uh, which was quite a bit larger. We had a couple of Capio clinics going over from Cambio. Uh, so, uh, we need those larger clinics also. And that's why I look forward to surgery e-referral when we have that module up and running because, um, typically, if you have surgery, then you have a much larger clinic so that we have large customers, uh, waiting. And we have great discussions with them, uh, and big interest from potential customers. So we have many potential customers in that project working with us, setting up those structures. So, um, but small customers, uh, they continue to add they're important because they drive net retention going forward. I mean, most start small and then they grow. So we need to continue with them. But to drive growth more in shorter periods, We also need large clinics and private hospitals moving to our systems.

Svein Martin Bjørnstad
42:08 - 42:36

And I would say also that the 21% growth for Webdoc, currency adjusted, is a good signal on this point that the momentum is very strong in Webdoc, compared to what we have seen in the last few years. Next question from Nicklaus. While your primary focus for acquisition is to make one in Germany, what opportunities do you see across your ecosystem in Sweden and Norway for add-ons?

Daniel Öhman
42:37 - 44:16

Yeah. So, there are a lot of interesting opportunities out there. I think there are a couple of different points here. The first one is that we cannot try to do too much at once. So, even if we have a list of acquisitions that we would like in this region, we're not actively pursuing it. I think also in the private market in general, especially in the Nordics, I feel, is that if you are profitable and you have a good cash flow, then and you don't need to sell your business, then prices haven't come down. They were all offered really good sums a couple of years ago, and they're not prepared to sell for less typically, so the price has not really changed to reflect the valuations that you see in, for example, a public company. When it comes to the ones not making a profit, and there are quite a lot of that after that. Boom. We had those a couple of years. They have come down a lot in price, but those are not the ones we want to buy. Typically they have business models which are not really working. And I think what many have made as mistakes is that they come from the outside and try to change how healthcare is provided too much. Healthcare is a slow-moving business when it comes to change. You cannot come in and try to disrupt it, especially not from the outside. That will not work. So I think that makes it also not the right time maybe to chase opportunities when it comes to acquisitions in the Nordics.

Svein Martin Bjørnstad
44:18 - 44:30

Great. We have a few questions from VGR. Have you seen any effects with customers from product improvements and are NPS etc. potentially going forward?

Daniel Öhman
44:31 - 45:52

Yeah, I think that Webdoc now growing at more than 20% is what you really see there. And the net retention rate where we can increase prices a little bit more than a year ago. So I think it was in January last year. I mean, I was a customer before, and all of us customers felt that Webdoc was a great product, but it felt like they didn't really care about us anymore as customers. They were focused on other things. So that was a general feeling, actually. And we spoke about competition between the competitors. And so the first thing I did was to invite, um, the chief digital officer of our largest customer, Capio, here. And he said that he doesn't need a lot of new functionality. I just need this system to really work and work well. And it was, uh, they were quite upset at that point in time that it did not work better, that we didn't fix things that needed to be fixed in the software. If you don't do anything, there would be more and more problems. You have to maintain it just to make sure that it works as well as it did yesterday, basically. And, and uh, now, a year later, they are really happy with the product. So we have completely different discussions with them and other customers. So that's where I feel in a really strong position. Um.

Svein Martin Bjørnstad
45:55 - 46:56

Yeah, yeah. Um, next question. What is your view of the long-term sustainable level of consulting revenue and its effect on EBITDA? Um, so, uh, in Q1 now, we had, um, uh, consulting revenues, uh, of around 8% of the total and recurring revenues were 92%. Given how we focus now, we expect recurring revenues to grow faster than consulting revenues. But we will always have, uh, some consulting revenues, uh, related to implementation. There could be specific projects for Medrave, etc. Um, but the most important focus is on, uh, the recurring revenues. Without being too specific. Next question. What is your view on the efficiency of resources deployed into Webdoc X with only one live customer?

Daniel Öhman
46:57 - 49:13

Right? Yeah. So, uh, we're not trying to get more live customers, uh, in general into Webdoc X at the moment. What we're really trying to do is to make sure that it's, uh, allowed and certified for the German market, and then we want to have live customers in that market. I think it's extremely important that we develop this system for a specific customer base and not try to build too wide a system. Uh, then you typically have issues with, uh, the customers not really liking the product you have, uh, developed. And that's what you see quite often. Uh, I would say, and part of the reason why we bring customers from other systems at the moment, uh, so, uh, but you can always discuss efficiency. We're trying to become more and more efficient. The team is now smaller than it was a year ago, and I think it's also working better. We've changed the entire structure around to have revenue management in place. Uh, and, uh, I feel that the team really knows what needs to be done. We now have a good, um, how to put it. Um, when it comes to software development, it's very important to make sure that, you know, you have a good pace of demand and that the developers can meet that demand. So you don't have any lags and that you have no one sitting idle at any point in time. And it's, uh, that's kind of the factory going on here. And uh, now within Webdoc X, we start to get that hum really going. Well, I think, uh, we had a lot of changes in the personnel there, uh, to make sure to get there. That team was, uh, employed maybe a bit too short time with the focus on just employing the entire team in a very short period of time, which created mayhem. Yeah, maybe we were not at that point in time as, um, careful enough as we should with employment, as you always need to be. So that's what we had to fix quite a lot there. Uh, but I feel now it's, uh, it's a much better team, uh, with a good internal pace and, uh, with more harmony than before.

Svein Martin Bjørnstad
49:15 - 49:31

So, uh, next one, what effects can be expected on communicating the targets for EBITDA with the potential, uh, German market entry? In 2024 and 2025. Yeah.

Daniel Öhman
49:31 - 50:28

So, uh, that includes, you know, uh, investments in those areas include investments in Germany. Uh, and with 20 million, uh, per year, roughly. Um, and. Uh, we feel that it's, uh, we do not include the acquisition in that. So that's why it's just negative. That part of the case, uh, aiming for acquisition. We don't have it yet, so we cannot put it into the numbers. But we're aiming to buy a profitable, uh, company, uh, which will help us scale up faster. Um, but. So, um, that should be a positive for those targets when we have that. And if we have that acquisition. Um, so, um, but this is the base case where we do not have it, and, and it's being rolled out, uh, quite slowly. Yeah.

Svein Martin Bjørnstad
50:28 - 51:06

And the targets now, uh, I would say, um, on the revenue side is a very limited effect from Webdoc X, but we have the 20 million in cost. But we of course aim to do. An acquisition that will make it potentially look quite different. Um, now we have quite a few questions from Medrave. Um, first one, could you comment on what you see in VGR? Com given the political landscape, usually slow, but has this impacted your customers yet and has it impacted new sales in the region.

Daniel Öhman
51:06 - 53:17

Yeah yeah. So VGR now. Uh uh, so private healthcare in Sweden is always quite political. It's always been active here since 2006. In this landscape, there has been a lot of talk but very little action. So the private sector has always grown because the private providers are cheaper than the public ones. It's easier for the region to deal with and yet provides more care for the taxpayers. Now, in regional Stockholm, for the first time, you see the Social Democrats actually trying to turn the tide. Never seen that before. And they are actually trying to take some of the care back into the public hospitals from the private providers. It will be much more expensive than the care they receive at the moment. But it's the first time I actually see that the number of private providers will decrease and are maybe decreasing in Stockholm. But at the moment, we have quite a few customers in Stockholm. So, it makes it a bit more difficult to sell. It's been like that for maybe a year now. So, it's a bit more challenging environment for selling. If we didn't have that situation, we would be able to sell more. Most of the providers today, at least those working towards the public, are now aiming to get insurance patients. Then, Webdoc X is an even better system for them. And they are also hoping, I think, to win tenders because the public hospitals will not be able to manage this. The public hospitals get a little bit less efficient every year. And the need for care increases all the time. So, we might have some short-term headwinds that we have. But in the longer term, I think it's a non-issue. And they will move back to the usual pace. But at the moment, it is a bit more difficult to sell. And it's been like that for about a year, I would say.

Svein Martin Bjørnstad
53:19 - 53:24

How has the response to the EU referral been so far?

Daniel Öhman
53:24 - 54:17

Yeah. So, the pilots are up and running now, as I mentioned earlier, they're very positive, maybe a bit too positive. It really saves a lot of time for them and decreases the risk for patient risks. When you process this by hand, you might miss patients. I know there was a patient, for example, where they missed giving a response in a cancer case because this was missing in the manual work there. It went okay for the patient. But it's not acceptable. These things happen. So now we're automated. It decreases risk. So that's quite good. And it will help us sell in Stockholm. It's a key part of it. It's not a standalone thing that makes you buy the system, but it's part of the whole thing that will help us and helps us drive sales.

Svein Martin Bjørnstad
54:18 - 54:28

Has the new Capio clinic signed? Due to the expected surgery e-referral module. Or is it tied to other underlying things such as improved downtime in referrals, etc.?

Daniel Öhman
54:28 - 55:06

Yeah, no. So it has nothing to do with the surgery e-referral module. I think it has more to do with the product improving, and that I feel that we really want to have customers in Sweden, that we are going after that and that we are improving the system all the time. So those clinics, they will not use the surgery e-referral module. We have to do some other development to automate reporting into the cataract registry for the eye clinics. We didn't have that before. We can sell it to also some of the existing clinics, that module. So that's a good thing. But we had to do some small development that we can then sell to all other customers also.

Svein Martin Bjørnstad
55:08 - 55:14

Next one. Babcock is selling strongly. Could you talk more specifically about the sales? What do you see here?

Daniel Öhman
55:14 - 56:56

So what I really look forward to is this patient journey I spoke about earlier. We have a product which we call Webdoc X, which is for the interaction with patients between the clinic and patients. And there you can, you know, have a chat with the patient. You can have video calls with patients. You can have the patient rebooking the appointment. You can send out forms. You can do a lot of things. And what's really key between Webdoc X and other similar solutions out there is that it's completely connected to the EHR system, WebSockets. So anything you do can connect directly into Webdoc X. So when you change the appointment, it changes within Webdoc X. If you chat with the patients, you can just press a button and it goes into the medical records. Otherwise, you have to transfer it by hand in different ways and in many systems. A good system doesn't allow you to use Ctrl+C, Ctrl+V for safety reasons. So, it's really a very efficient system, but we've been selling it as singular functions. And caregivers are not the most inventive. So if you try and sell, you should sell a chat. It doesn't really help them very much. But if you sell a complete customer experience and how that can drive efficiency in their world and really show that and we set it up for them, then I really believe in that product and that we can really launch it. And there are some smaller things we have to do to make sure that that is a seamless experience. So that's the aim now, and I think that could really drive up sales. So will the Circle module. Um, was adding new partners in the network that will help us drive up sales.

Svein Martin Bjørnstad
56:57 - 57:28

And I think another part that has driven it is that upsell has been quite strong for a period. But we also last year had quite big drawdowns in volume after the pandemic. So that volume growth is now more stable than it was last year as well. Next one, do you see a chance of a larger contract for Medrave as well, given that the region has also procured the same public EHR system?

Daniel Öhman
57:28 - 58:44

As you know, Medrave has a different type of contract. So, it will not be a completely new contract with them to, to give a mandate to Medrave in the corner. So no, it will not be the case. They will have Medrave also in the corner. Um, and they will continue to have Medrave. Uh, we are setting it up for them at the moment. Um, but in general and insurance corner, I think we need to look over the pricing of Medrave everywhere. We have improved the system a lot, and now we haven't really charged our customers for it fully. I think, uh, and it's creating a lot of value for our customers. So, uh, we will not have a new large contract with Medrave, but I see the opportunity in general to increase prices within Medrave. Uh, but, uh, we're analyzing it at the moment. Uh, we also have many different types of contracts in that, in that product. I mean, more than 90% of all primary care really use Medrave. So, um, uh. It will be stepwise and will be at different times, at different contracts and so on. But in general, I see a good opportunity to increase prices within our market.

Svein Martin Bjørnstad
58:45 - 58:50

And next, an update on the process of finding an acquisition in Germany.

Daniel Öhman
58:51 - 59:37

Yeah, we have, I think, good discussions. I think every time we're there, we feel more and more strongly about this opportunity. Uh, we're very positive about, uh, that it's the right time to enter Germany. Uh, and we have good discussions, but this is the challenge with M&A. It's not, uh, it's black and white. So, you never, you know, you never partially do it. You do it or don't do it. And it's always important that we are ready to back off if we find something or see something that we don't like or if the negotiation doesn't go well enough. So, uh, it will be very difficult to give a proper update until it's done or not done. Uh, do you.

Svein Martin Bjørnstad
59:37 - 59:40

See good acquisition targets in the Nordic region, too?

Daniel Öhman
59:40 - 59:41

I think I responded to it earlier.

Svein Martin Bjørnstad
59:42 - 59:47

Could you comment more on the sales progress of Alturas and another product?

Daniel Öhman
59:47 - 61:00

Yeah. So, uh, those products need more customers. Uh, and I think we have good discussions and, uh, a good likelihood of at least one, a bit larger contract, uh, for one of those products within the coming months. Uh, and then we would have one of those products under control, which would feel really good. And we need it. Uh, otherwise, we need to do other things, uh, adapt with lowered costs. Uh, quite a lot. And we're rolling out Adobe Web. Uh, we have some, uh, parts which are not really developed enough to provide that customer experience we need to give, uh, especially when it comes to logging in and logging out. The system is not stable enough. Um, but we should be there within short. Uh, um, we just had a customer survey, and they were open. Web users are quite happy; they don't like, but in other services, they're really happy with the system. So I'm optimistic still. But we are a bit behind schedule on that project.

Svein Martin Bjørnstad
61:02 - 62:19

Uh, next one from Filip. What gives you confidence in the 15% growth during 2024? As I understand it, most larger contracts will contribute starting in 2025. Uh, so for 2024, we, uh, of course, have quite good visibility at the moment. And the growth we target is quite close to the run rate. We are at, uh, at 67 million in, in, in Q1, uh, and we expect some growth during the year as well. Uh, but it's correct that the larger contracts for VGR and, um, that will have the main impact in 2025, although the contracts will start generating revenues in Q4 already. Um. You are saying from Daniel to me, you are saying that most of the growth included in your updated targets are already secured. But can you say something about how much, how much of the growth with new contracts will contribute in 2024 and 2025? Um, yeah.

Daniel Öhman
62:19 - 62:19

So.

Svein Martin Bjørnstad
62:20 - 63:18

Um, the new contract is basically why we target the higher growth in 2025 or 20%. It's around, um, in 2024, we expect to grow around 35 million nominally new from um, if we adjust for last year. And then if we take that the same growth, which is basically how we have been growing the last few years, uh, and add the new contracts, then we, we come to the 2025 figure. So, so we have to continue to succeed at the same pace that we have done historically and then add the new large contracts on top of that basically. Next one. What is your best guess on the timing of the new system in Stockholm, and when do you expect to see effects from this process on your sales?

Daniel Öhman
63:19 - 65:33

Yeah. So, uh, I mentioned it briefly before, but it's, uh, it's being tested at the moment. Uh, it's to be implemented around 2029 somewhere. That the plan is to produce or typically, you know, delayed by 2 or 3 years. Uh, I think Stockholm is a bit more difficult than it usually is at the moment because, uh, you have some care that the region is trying to move from the private to the public side. And also you have that the caregivers don't really know what will happen. Uh, with the new system, they don't know what their options will be. So I mean, they are comparing Webdoc X with something. They don't know what it is yet. Uh, so I think that as we get closer to that point in time, it will be easier to sell. Uh, I mean, we're selling quite okay anyway, but it is actually quite a difficult environment to sell in at the moment. Um, and, uh, but that will take some time because 2029 is some way off. And this is the third time I think they try to turn this system. Uh, so. I think that clarity and that things get clear are always good. Uh, when our customers don't really know what the options are and what's happening, they tend to wait with big decisions like this, with changing systems, that is. So I think it is, uh, affecting us negatively. Uh, I think we just need to realize that that's how the market is, and just make sure that our system is even better so that you. Anyways, um, chooses to change systems and we are taking customers in Stockholm, will continue to take customers in Stockholm. And I think we can increase when it comes to surgery e-referral. A lot of that is in Stockholm. And because surgery e-referral is a big part of care, that's what you typically don't pay out of pocket for. So if you look at a smaller region that doesn't put as much emphasis on care from private providers, then you will typically have a lot of outpatient services and less surgery e-referral. In Stockholm, you have a lot of surgery within the private setting, so the ceremony will be important. This document, specifically.

Svein Martin Bjørnstad
65:34 - 65:58

Uh, next, one another on the potential German acquisition. Uh, how many targets would you say are ticking all the boxes of the requirements you mentioned? And would you expect that several of the legacy systems are complex, given that you typically see that systems grow in complexity over the years?

Daniel Öhman
65:59 - 66:50

Yeah. Yeah, that's partly true. Uh, so the German market for health systems is extremely fragmented. Um, you have C-Medical owning 30% of the market, but that's not one system. That's so many differences, um, that I acquired and not really invested in, so and not kind of pushing them together, what we can see to a major extent. So, they own a lot of systems. Uh, and then there are a lot of small systems, uh, out there. So the potential list is really long and, and uh, as you mentioned in the question, you're completely right there. It's important, um, it's important to make sure that what we buy does not have too much complexity. And that's something we really have to look carefully at when buying systems. Thanks. So and I think we had.

Svein Martin Bjørnstad
66:50 - 67:01

Talked a little bit about but on your ecosystem of third-party applications, I don't see any developments here, new interesting applications, or any existing applications that are gaining traction.

Daniel Öhman
67:01 - 67:56

Yeah. So I think what is gaining traction, I think we can do much more to make it gain traction more. Um, uh, we have a new partner we're working with, with, uh, using some AI in speech recognition, which is maybe a bit more popular than the ones we used to sell. So that's improving. Um, uh, the second source we're selling, or actually, we're losing some customers and we're moving them to VGR. We're trying to move them to instead. So I think that's a positive. It gives us a bit less revenue but more profitability. So, uh, because with VGR you don't have a fiscal shortage and you don't need to have that anymore. So, uh, it hurts revenue a bit, but it's good for profitability, that move. Um, and yeah, we are working with new partners all the time. Uh, but I think those are the most important changes.

Svein Martin Bjørnstad
67:57 - 68:05

Um, and then the final question from Pat there, you are not making any changes to your long-term guidance, correct?

Daniel Öhman
68:06 - 68:45

Uh, now, that's not correct. So we used to have, uh, a goal three years in the future, kind of with the average forecast; now with increased visibility, uh, we can give a much more precise guidance, but we're giving it for this year, next year. So this means that we do not have a goal for the year after that. Yet we see this. We are very positive and optimistic, as you can hear. Uh, but we don't have the same visibility on three years in the future as we have on two years in the future. So we are replacing the old targets fully and now have much more granular targets for the coming two years.

Svein Martin Bjørnstad
68:46 - 68:50

Okay, that was the final question. You want to wrap up?

Daniel Öhman
68:51 - 69:00

No. Uh, thank you all for listening. If you have any questions or comments, just reach out. So I look forward to hearing from you. So have a good day. Thank you, thank you.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…